Phase 1b Trial of LTI-01 (Single Chain Urokinase Plasminogen Activator, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions (CPE) or Empyema
Main Authors: | Idell, S, Beckert, L, Brockway, B, Simpson, G, Southcott, A, Lee, Y, Rahman, N, Light, R, Shoemaker, S, Gillies, J, Komissarov, A, Florova, G, Sarva, K |
---|---|
Format: | Conference item |
Published: |
American Thoracic Society
2019
|
Similar Items
-
Intrapleural and plasma processing of LTI-01 (single chain urokinase Plasminogen Activator, scuPA) in a phase 1b trial of LTI-01 Intrapleural Fibrinolytic Therapy (IPFT) in patients with Complicated Parapneumonic Effusions (CPE) or empyema
by: Komissarov, A, et al.
Published: (2019) -
Phase I trial of the single-chain urokinase intrapleural LTI-01 in complicated parapneumonic effusions or empyema
by: Beckert, L, et al.
Published: (2019) -
Precision-guided, personalized intrapleural fibrinolytic therapy for empyema and complicated parapneumonic pleural effusions: The case for the fibrinolytic potential
by: Idell, S, et al.
Published: (2017) -
Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models
by: Komissarov, A, et al.
Published: (2016) -
Intrapleural fibrinolytic therapy for empyema and pleural loculation: knowns and unknowns
by: Idell, S, et al.
Published: (2018)